Diabetes, Vol 38, Issue 6 779-783, Copyright © 1989 by American Diabetes Association

ARTICLES

Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes

JJ Cook, I Hudson, LC Harrison, B Dean, PG Colman, GA Werther, GL Warne and JM Court
Department of Endocrinology and Diabetes, Royal Children's Hospital, Victoria, Australia.

A double-blind controlled trial of azathioprine (2 mg.kg-1.day-1) was conducted with 49 patients aged 2-20 yr (mean 10.8 yr) who had newly diagnosed type I (insulin-dependent) diabetes. Patients were randomly assigned to receive either azathioprine (n = 24) or placebo (n = 25) for 12 mo, beginning within the 20-day period after diagnosis. Baseline clinical and metabolic characteristics did not differ between the two groups. No patient experienced complete remission, defined as restoration of normal carbohydrate tolerance without other treatment. Partial remission, defined as good metabolic control (hemoglobin A1c less than or equal to 7.9%, preprandial blood glucose less than or equal to 8 mM with an insulin dose of less than 0.5 U.kg-1.day-1), occurred in 10 placebo (40%) and 7 azathioprine (29%) patients at 6 mo and in 4 placebo (16%) and 4 azathioprine (17%) patients at 12 mo (differences not significant). Fasting plasma C-peptide was significantly greater in the azathioprine-treated group at 3 and 6 mo, but this difference was not sustained. C-peptide responses to a standard meal and the frequency of islet cell and insulin antibodies did not differ between the two groups over the 12-mo period. Azathioprine caused no significant side effects. We conclude that in the dosage used, and despite early effects on endogenous insulin secretion, azathioprine alone does not influence the remission phase in children with newly diagnosed type I diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Ethics of Hematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus--Reply JAMA, July 18, 2007; 298(3): 285 - 286. [Full Text] [PDF]

				J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 11, 2007; 297(14): 1568 - 1576. [Abstract] [Full Text] [PDF]

				P. Narendran, E. Estella, and S. Fourlanos Immunology of type 1 diabetes QJM, August 1, 2005; 98(8): 547 - 556. [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]

				D. M. Nathan The Impact of Clinical Trials on the Treatment of Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1929 - 1937. [Abstract] [Full Text] [PDF]